AVTE — Aerovate Therapeutics Share Price
0.000.00%
Last trade - 00:00- $703.26m
- $580.82m
- 19
- 14
- 91
- 36
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.43 | ||
| Price to Tang. Book | 6.43 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -74.16% | ||
| Return on Equity | -63.95% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH), a devastating disease impacting approximately 70,000 people in the United States and Europe. Oral imatinib also demonstrated statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in PAH patients. AV-101, delivered using a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. PAH is an orphan disease with unmet medical needs and is characterized by high pressure in the vessels transporting blood from the right side of the heart to the lungs.
Directors
- Mark Iwicki NEC (54)
- Benjamin Dake PRE (45)
- Timothy Noyes CEO (59)
- George Eldridge CFO (58)
- Hunter Gillies OTH (55)
- Ralph Niven OTH (61)
- Allison Dorval IND (46)
- David Grayzel IND (53)
- Maha Katabi IND (47)
- Joshua Resnick IND (46)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 27th, 2018
- Public Since
- June 30th, 2021
- No. of Shareholders
- 13
- No. of Employees
- 51
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 27,862,961
- Address
- 930 Winter Street, Suite M-500, WALTHAM, 02451
- Web
- https://www.aerovatetx.com/
- Phone
- +1 6174432400
- Auditors
- KPMG LLP
Upcoming Events for AVTE
Q2 2024 Aerovate Therapeutics Inc Earnings Release
Similar to AVTE
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Aerovate Therapeutics share price?
As of Today at 19:00 UTC, shares in Aerovate Therapeutics are trading at $25.24. This share price information is delayed by 15 minutes.
How has the Aerovate Therapeutics share price performed this year?
Shares in Aerovate Therapeutics last closed at $25.24 and the price had moved by +39.91% over the past 365 days. In terms of relative price strength the Aerovate Therapeutics share price has outperformed the S&P500 Index by +12.99% over the past year.
What are the analyst and broker recommendations for Aerovate Therapeutics?
The overall consensus recommendation for Aerovate Therapeutics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Aerovate Therapeutics dividend yield?
Aerovate Therapeutics does not currently pay a dividend.
Does Aerovate Therapeutics pay a dividend?
Aerovate Therapeutics does not currently pay a dividend.
When does Aerovate Therapeutics next pay dividends?
Aerovate Therapeutics does not currently pay a dividend.
How do I buy Aerovate Therapeutics shares?
To buy shares in Aerovate Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aerovate Therapeutics?
As of the previous close price of $25.24, shares in Aerovate Therapeutics had a market capitalisation of $703.26m.
Where are Aerovate Therapeutics shares listed?
Here are the trading details for Aerovate Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: AVTE
What kind of share is Aerovate Therapeutics?
Based on an overall assessment of its quality, value and momentum Aerovate Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aerovate Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Aerovate Therapeutics is $44.67. That is 76.98% above the last closing price of $25.24.
Analysts covering Aerovate Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.02 for the next financial year.
What is the trend in the Aerovate Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aerovate Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +95.88%.
As of the last closing price of $25.24, shares in Aerovate Therapeutics were trading +42.2% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aerovate Therapeutics PE Ratio?
The Aerovate Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $25.24.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aerovate Therapeutics?
Aerovate Therapeutics' management team is headed by:
- Mark Iwicki - NEC
- Benjamin Dake - PRE
- Timothy Noyes - CEO
- George Eldridge - CFO
- Hunter Gillies - OTH
- Ralph Niven - OTH
- Allison Dorval - IND
- David Grayzel - IND
- Maha Katabi - IND
- Joshua Resnick - IND